In 2019, CPhI South East Asia will take place at the Queen Sirikit National Convention Center (QSNCC) in Bangkok, Thailand before returning to Jakarta International Expo in Indonesia in 2020
CPhI South East Asia – organised by UBM – has announced from 2019 onwards it will alternate its annual location between the region’s two largest pharma economies, Indonesia and Thailand.
In 2019, CPhI South East Asia will take place at the Queen Sirikit National Convention Center (QSNCC) in Bangkok, Thailand (12-14 March) before returning to Jakarta International Expo (JIExpo) in Indonesia in 2020 (4-6 March).
CPhI South East Asia’s strategic move to Thailand will further strengthen the event’s appeal within the region. Organisers’ anticipate a significant growth in new visitors from more diverse locations with the new venue, catering to attendees that were previously unable to participate.
The event's first visit to Thailand comes at a significant time for the country, as pharma sales are expected to grow by 8.4% in 2019, with multinational corporations looking to partner with local contract manufacturers in order to expedite and streamline market access.
According to data from BMI Research, by 2021 the pharmaceutical market is forecast to reach a value of THB209.7 bn ($6.3 bn), experiencing a compound annual growth rate of 5.4% in local currency terms and 6.8% in US dollar terms. In the extended forecast period, medicine sales will experience a 10 year CAGR of 5.5% and 6.3% in local currency and US dollar terms respectively, reaching THB275.2 bn ($8.4 bn) by 2026.
CPhI South East Asia, which just celebrated its seventh year, will co-locate in 2019 with FDF, ICSE, P-MEC, InnoPack, and the returning LABworld South East Asia – following a successful opening year. UBM forecasts the inaugural edition in Bangkok will host more than 6000 attendees and 270 exhibitors.
Executives will come from across the region’s fastest growing industries including pharma ingredients professionals, packaging experts, machinery providers and contract manufacturing, as well as nutraceutical companies and laboratory specialists – facilitating a collective environment that is designed to stimulate the next stage in the ASEAN pharma expansion.